Literature DB >> 6812750

Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.

E Stranden, O K Roald, K Krohg.   

Abstract

The selective 5-hydroxytryptamine2-(5-HT2)-receptor-blocking agent ketanserin was given in a dose of 10 mg intravenously to nine patients with Raynaud's phenomenon. The effect on blood flow was assessed by photopletysmography and measurments of skin temperature. Digital blood flow and skin temperature increased significantly after ketanserin injection, whereas the placebo (saline 9 g/l) had no such effect. This study suggests that ketanserin may be useful in the treatment of Raynaud's phenomenon.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6812750      PMCID： PMC1500031          DOI： 10.1136/bmj.285.6348.1069

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


  6 in total

1.  Vasospastic diseases: a review.

Authors:  J D Coffman; W T Davies
Journal:  Prog Cardiovasc Dis       Date:  1975 Sep-Oct       Impact factor: 8.194

Review 2.  Raynaud syndrome.

Authors:  R J Blunt; J M Porter
Journal:  Semin Arthritis Rheum       Date:  1981-05       Impact factor: 5.532

3.  Pathophysiology of Raynaud's disease.

Authors:  J L Halperin; J D Coffman
Journal:  Arch Intern Med       Date:  1979-01

4.  Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.

Authors:  G J Wenting; A J Man in 't Veld; A J Woittiez; F Boomsma; M A Schalekamp
Journal:  Br Med J (Clin Res Ed)       Date:  1982-02-20

5.  Raynaud's disease, Raynaud's phenomenon, and serotonin.

Authors:  A HALPERN; P H KUHN; H E SHAFTEL; S S SAMUELS; N SHAFTEL; D SELMAN; H G BRICH
Journal:  Angiology       Date:  1960-06       Impact factor: 3.619

6.  Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in the isolated femoral artery of the rabbit; effect of ketanserin (R 41 468).

Authors:  J M Van Nueten; P A Janssen; A De Ridder; P M Vanhoutte
Journal:  Eur J Pharmacol       Date:  1982-02-05       Impact factor: 4.432
  6 in total
  17 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Ketanserin in the treatment of traumatic vasospastic disease.

Authors:  V H Larsen; J Fabricius; G Nielsen; K S Hansen
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-13

Review 3.  Pathogenesis and treatment of Raynaud's phenomenon.

Authors:  J D Coffman
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

4.  Prolongation of the QT interval by ketanserin.

Authors:  H A Cameron; P C Waller; L E Ramsay
Journal:  Postgrad Med J       Date:  1988-02       Impact factor: 2.401

5.  Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy.

Authors:  J J Kunnen; H P Dahler; J G Doorenspleet; J C van Oene
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Circulating lupus type anticoagulant and pulmonary hypertension associated with mixed connective tissue disease.

Authors:  P Hainaut; E Lavenne; J M Magy; E G Lebacq
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

7.  Treatment of Raynaud's phenomenon with large doses of triiodothyronine: a pilot study.

Authors:  P H Dessein; R F Gledhill
Journal:  Ann Rheum Dis       Date:  1987-12       Impact factor: 19.103

8.  Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.

Authors:  O K Roald; E Seem
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-08

9.  Cold-induced Raynaud's phenomenon ameliorated by intravenous administration of ketanserin: a double-blind cross-over study.

Authors:  H Baart de la Faille; H van Weelden; J D Banga; R G van Kesteren
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

10.  Digital blood flow and 5-hydroxytryptamine receptor blockade after ketanserin in patients with Raynaud's phenomenon.

Authors:  B Marasini; C Bassani
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.